Yahoo
OTC Markets OTCID USD

ProPhase Labs, Inc. (PRPH)

0.0075 -0.0005 (-6.25%)
At close: October 30 at 12:19:44 PM EDT
Chart Range Bar
Loading chart for PRPH
  • Previous Close 0.0080
  • Open 0.0080
  • Bid 0.0075 x 2000000
  • Ask 0.0080 x 38435300
  • Day's Range 0.0075 - 0.0080
  • 52 Week Range 0.0075 - 3.9000
  • Volume 71,742
  • Avg. Volume 327,921
  • Market Cap (intraday) 116,944
  • Beta (5Y Monthly) 0.14
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8700
  • Earnings Date (est.) Nov 16, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date May 24, 2022
  • 1y Target Est --

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.

www.prophaselabs.com

19

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRPH
98.33%
S&P 500 (^GSPC)
10.73%

1-Year Return

PRPH
99.80%
S&P 500 (^GSPC)
11.11%

3-Year Return

PRPH
99.98%
S&P 500 (^GSPC)
81.91%

5-Year Return

PRPH
99.99%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY25
Revenue 1.25M
Earnings --
Profit Margin 0.00%

Q3

FY24

Q4

FY24

Q1

FY25

Q2

FY25

0
1M
2M
3M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -19.56%

  • Return on Equity (ttm)

    -539.65%

  • Revenue (ttm)

    3.85M

  • Net Income Avi to Common (ttm)

    -22.46M

  • Diluted EPS (ttm)

    -0.8700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    47.52M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: